AstraZeneca Wins Patent Infringement Case Against Pfizer, Vacates $107.5M Jury Award

AstraZeneca's Victory:
AstraZeneca successfully vacated a $107.5 million jury award in a patent infringement case against Pfizer.

Court Decision:
The US court ruled in favor of AstraZeneca, erasing the jury award that was initially granted to Pfizer.

Patent Dispute:
The case involved a dispute over patents related to AstraZeneca's drug, with Pfizer's subsidiary Wyeth LLC claiming infringement.

Legal Proceedings:
The decision came after a five-day jury trial in the US District Court for the District of Delaware, where AstraZeneca argued against the validity of the patents in question.

Impact:
This ruling is a significant legal victory for AstraZeneca, potentially affecting the pharmaceutical industry's approach to patent disputes and litigation.